Skip to content
Clinical Trials – home

Syphilis Trials in Disease

0 / 3 trials open to patients3 countries

In short

There are currently 2 ongoing clinical trials studying new treatment approaches for syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum. These studies are taking place in France and Spain, comparing oral antibiotics with the standard injection treatment to find effective alternatives for patients with early-stage infection.

Clinical trial locations

Study Comparing Doxycycline and Benzathine Benzylpenicillin for Treating Early Syphilis in Adults

This trial is being conducted in France and focuses on finding an effective oral treatment option for people with early syphilis. The study compares two different antibiotic treatments to determine if they work equally well.

Main goal: The primary aim is to determine whether taking doxycycline tablets twice daily for 14 days is as effective as receiving a single injection of benzathine benzylpenicillin. Success is measured by checking whether the infection markers in the blood have decreased significantly after six months of treatment.

Who can participate: Adults aged 18 years or older with confirmed early syphilis can join this study. This includes people with primary syphilis (characterized by painless sores), secondary syphilis (with skin rashes), or early latent syphilis (infection present for less than one year without visible symptoms). Participants may have HIV infection or not. They must have a positive result on a specific blood test called a non-treponemal assay and be able to attend follow-up visits for six months. Participants must also be covered by the French health insurance system.

Who cannot participate: People who do not have early syphilis, those outside the specified age range, and individuals considered part of vulnerable populations who cannot provide informed consent are excluded from this study.

Investigational treatments: The study uses two antibiotics. Doxycycline is an oral antibiotic taken as a tablet twice daily. It works by stopping bacteria from growing. Benzathine benzylpenicillin (BPG) is given as a single muscle injection and kills the bacteria causing the infection. This is the standard treatment currently used, and the study will compare whether doxycycline can be an equally effective alternative.

Study of Linezolid and Benzathine Benzylpenicillin for Treating Patients with Early Syphilis

Taking place in Spain, this clinical trial explores whether an oral antibiotic called linezolid can serve as an effective alternative to the standard injection treatment for early syphilis.

Main goal: The study aims to determine if linezolid taken orally is as effective as benzathine benzylpenicillin injections in curing early stages of syphilis. Researchers will monitor the healing of syphilis sores and track changes in blood test results that indicate the infection's presence. They will also check for any recurrence of the infection by testing for bacterial DNA. The study examines both the effectiveness and safety of the two treatments.

Who can participate: Adults aged 18 years or older with confirmed early syphilis can join this study. This includes people with primary syphilis (identified by a typical sore and positive tests), secondary syphilis (identified by typical symptoms and positive blood tests), or early latent syphilis (positive blood tests without symptoms, with evidence of recent infection within the past year). Participants must sign an informed consent form and be able to follow study requirements. Women who can become pregnant must use highly effective birth control methods, such as abstinence, birth control pills, or intra-uterine devices, for one week after completing the medication. Male participants must use condoms during sexual activity and ensure their female partners use effective birth control for one week after the last dose.

Who cannot participate: Individuals not diagnosed with early syphilis, those outside the specified age range, and people who are part of vulnerable populations requiring special protection cannot participate in this study.

Investigational treatments: The study compares two antibiotics. Linezolid is an oral antibiotic being tested for its ability to treat early syphilis. It has the advantage of penetrating the nervous system, which may be beneficial if the infection affects the brain or nerves. It works by stopping bacteria from making proteins they need to survive. Benzathine benzylpenicillin (BPG) is the standard injection treatment for early syphilis and serves as the comparison treatment in this trial.

Summary

Both ongoing trials focus on finding oral antibiotic alternatives to the standard injection treatment for early syphilis. The French study tests doxycycline, while the Spanish study evaluates linezolid. Both compare these oral medications against benzathine benzylpenicillin, which is currently the established treatment given as a single injection.

These studies are important because they may provide patients with more convenient treatment options. Oral medications taken at home could be easier for some patients compared to receiving injections at medical facilities. Both trials carefully monitor participants over several months to ensure the treatments are effective and safe.

The trials accept adults with different stages of early syphilis, including primary, secondary, and early latent forms. Both studies require participants to be at least 18 years old and able to attend regular follow-up visits. The research includes people with and without HIV infection, recognizing that syphilis can affect different patient populations.

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Syphilis

Recruiting trials first

See all 3 trials →
Quick filters

3 clinical trials in this condition

Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Doxycycline Monohydrate
  • Sponsor:Institute Of Tropical Medicine

Syphilis

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Linezolid
  • Sponsor:Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia

Syphilis

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Benzathine Benzylpenicillin
  • Sponsor:Assistance Publique Hopitaux De Paris
See all 3 trials →filters applied: condition = Syphilis

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).